The specific inhibition of HDAC6 by novel HDAC6i drugs including ACY-738, have provided degrees of neuroprotective effects in models of MS, CMT and FUS-ALS [20,21,24,25,32]. This evidence concerns the gene HDAC6 and myeloid sarcoma.